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Aplidine, a cyclic peptide, from the tunicate Aplidium albican, prevents the in vitro aggregation into h-sheet containing fibrils of the prion
peptide 106–126 when co-incubated in a 1:1 molar ratio. The blocking of fibril formation induced by Aplidine has clear sequence specificity,
being much stronger for the 106–126 prion peptide than for the h-amyloid 25–35 peptide. In addition to the known ability of Aplidine to
cross the plasmatic membrane, these results indicate that Aplidine is a potential leading compound for the development of therapeutic
blockers of prion aggregation.
D 2003 Elsevier B.V. All rights reserved.Keywords: Aplidine; Prion peptide; Inhibition of aggregation1. Introduction
Prion diseases are a group of typically fatal neurodegen-
erative diseases clinically characterized by the appearance of
spongiform lesions in the central nervous system (CNS).
Members of this group are diseases affecting humans:
Creutzfeldt–Jakob disease, fatal familial insomnia, Gerst-
mann–Straussler–Scheinker disease and kuru, as well as
others affecting animals, such as scrapie and bovine spongi-
form encephalopathy [1]. The manifestation of the disorder
can have a genetic origin, arise sporadically, or even be
caused by infectious transmission [2]. In all these cases, the
disorder is accompanied by a structural modification of the
cellular, primarily a-helical, prion protein (PrPC) into an
aggregated and protease-resistant form that displays a high
h-sheet content (PrPsc) [3–5].
The prion hypothesis, which was distinguished with the
Nobel Prize to Stanley Prusiner in 1997, states that it is the
change in protein conformation from PrPC to PrPsc which
causes the disease and transforms the cellular PrP protein0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2003.08.003
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E-mail address: javila@cbm.uam.es (J. A´vila).into a novel class of infectious particle. The definitive proof
for the prion hypothesis, namely the chemical transforma-
tion of normal PrP protein into infectious particles, has not
been achieved yet. However, during the last two decades, a
large body of evidence supporting this hypothesis has been
assembled [6]. Clinical correlations have been found be-
tween the onset of the disease and the appearance of PrPsc
deposits in brain tissue [7,8]. The infectious particles are
mainly composed of the same aggregates of PrP in an
abnormal conformation, and do not include significantly
sized nucleic acids [3,9]. A simple protein-only mechanism
of replication and transmission has been proposed that
involves recruitment of normal PrP protein to form new
infectious particles [3,6]. Genetic modified mice experi-
ments reveal that expression of PrPC protein is, indeed,
required for the onset of the disease [10].
However, only a fraction of the prion protein seems to
be involved in all these processes. The major component
extracted from amyloid inclusions of GSS brain tissue is a
7 kDa fragment comprising residues 88–153 of the prion
protein [11]. A smaller fragment comprising residues 90–
144 appears to be able to initiate the prion disease in vivo
when it carries the P102L substitution (a GSS-linked
mutation) [12]. Furthermore, the region involved in the
conformational change only encompasses residues 106–
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includes two short h-strands [1] that are thought to elongate
upon conversion into PrPsc. Peptides corresponding to
segments of the 106–141 region aggregate forming h-
structure in vitro [13], suggesting that the conformational
change can be replicated without the context of the whole
protein. One of such peptides—i.e. peptide 106–126—has
been shown to kill neuronal cells in culture after formation
of extracellular h-sheet-containing aggregates [3,14,15].
Furthermore, the formation of h-sheet structure in peptide
106–126 requires a pH of f 5, in agreement with the
hypothesis that the transformation into PrPsc occurs in the
lysosomes [1,16].
For these reasons, region 106–141 of PrP has often been
used as a target for developing and testing molecules with
potential therapeutic activity against PrPsc. Peptides from
this region inhibit the in vitro incorporation of recombinant
PrP into PrPsc particles [17], probably by sequestering PrP
into peptide aggregates. In a more recent report, it was
shown that peptides originating from this region and mod-
ified with several prolines to act as h-sheet breakers were
capable of dissolving infectious PrPsc [18]. Moreover, co-
incubation of PrPsc with these h-breaker peptides decreased
the infectivity of PrPsc and delayed the onset of clinical
symptoms of scrapie in animal models [18].
In this report, we take a different approach. Instead of
using analogs of the PrP sequence as a base for finding
possible inhibitors of PrP aggregation, we look for more
generic drugs known to act as h-breakers. In particular, we
have tested the inhibitory effect of the marine drug
Aplidine [7], a proline-containing cyclic peptide isolated
from the tunicate Aplidium albican [19], on the in vitro
aggregation of peptide PrP 106–126 into h-sheet fibrils.
We find that Aplidine is a strong inhibitor of the aggre-
gation of PrP 106–126, showing measurable effects even
at f equimolecular concentrations. Moreover, the effect of
Aplidine on the aggregation of the h-amyloid peptide,
another h-sheet fibril-forming peptide [20], is much less
pronounced, indicating specificity of action against the PrP
106–126 sequence.2. Materials and methods
2.1. Materials
Aplidine was provided by PharmaMar (Madrid, Spain).
2.2. Assembly of peptides
In vitro polymerization experiments of PrP 106–126,
and h-amyloid 25–35 peptides have been performed as
previously indicated [14,15,21]. Briefly, filaments were
grown by vapor diffusion in hanging drops in the standard
way used for protein crystallization [22]. Ten micrograms of
PrP 106–126 (1 mg/ml final concentration), or increasingamounts from 0 to 5 Ag of h-amyloid 25–35 peptide
(concentrations between 0 and 0.5 mg/ml) were dissolved
in 10 Al of Buffer A (0.1 M MES (pH 6.4), 0.5 mM MgCl2
and 2 mM EGTA) plus 50 mM NaCl. The reservoir
contained 0.2 M NaCl in buffer A. The hanging drops were
incubated for 4 days at 4 jC.
2.3. Effect of Aplidine in peptide assembly
Tests of the inhibitory effect of Aplidine in peptide
assembly were performed by adding Aplidine and the PrP
or h-amyloid peptides simultaneously to the same incuba-
tion buffer described above. The hanging drops were
incubated for 4 days at 4 jC. Tests of the effect of Aplidine
in preformed fibrils of PrP peptide were carried by adding
Aplidine at a final concentration of 500 AM to samples
containing fibrils assembled by the standard hanging drop
procedure (as explained in the previous paragraph). The
samples were incubated with Aplidine up to 2 h at room
temperature, and then inspected by electron microscopy.
2.4. Fourier transformed infrared (FTIR) spectroscopy
All the infrared absorption spectra were obtained in
aqueous solution using a Digilab Excalibur FTS 3000 FTIR
spectrometer equipped with a Harrick ConcentratIR hori-
zontal multiple reflection (ATR) [23]. This accessory is
specially designed to carry out FTIR measurements of very
small volumes of liquid by producing 14 infrared reflections
within a 4-mm diameter area. For each spectrum, 512
interferograms at 4 cm 1 resolution were co-added, and
Fourier-transformed using triangular apodization. Samples
of PrP 106–126 were prepared by dissolving 0.25 mg of
peptide in 25 Al of PBS buffer plus either 5 Al of DMSO, or
5 Al of a 200 mg/ml Aplidine solution in DMSO. The
samples were incubated overnight at 37 jC, then freeze-
dried and resuspended in 30 Al of D2O to carry out the FTIR
measurements. h-Amyloid 25–35 samples were prepared
exactly in the same way, but using water instead of PBS
buffer.3. Results
Fig. 1A shows a negative-staining electron micrograph of
a sample of f 430 AM PrP 106–126 in conditions known
to induce aggregation into h-sheet containing fibrils (see
Materials and methods). The image shows large amounts of
long fibrillar aggregates that tangle up into a rather dense
mesh. The overall dimensions of these filaments, with a
diameter of 6–8 nm, correspond to those previously de-
scribed for PrP 106–126 [15]. Addition of Aplidine in a 1:9
ratio, at the beginning of the incubation, is sufficient to
perturb the formation of PrP 106–126 aggregates, resulting
in shorter fibrils (mainly of 8 nm) that also accumulate in
lower amounts (Fig. 1B). In equimolecular, or higher,
Fig. 1. Polymerization of PrP peptide in the absence and presence of Aplidine. All the in vitro polymerization experiments were carried out at final PrP 106–
126 concentrations of f 430 Am (i.e. 1 mg/ml) as described in Ref. [15]. (A) PrP 106–126 aggregates incubated in the absence of Aplidine. (B) As in A, but
co-incubated with Aplidine at a final concentration of 50 AM, (C) as in A, but co-incubated with Aplidine at a concentration of 500 AM. (D) Aplidine alone. (E)
PrP 106–126 aggregates co-incubated with 10 mM proline. (F) Schematic representation of the chemical structure of Aplidine. Bars indicate 500 nm.
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cantly sized aggregates could be detected by electron
microscopy (Fig. 1C). Quantification of the amount of
aggregated material by measuring the amount of sedimented
peptide after centrifugation [15] confirms these conclusions
(data not shown). As a negative control, we performed the
same assay with only Aplidine and no PrP peptide, which
rendered no aggregates detectable by electron microscopy
(Fig. 1D). Because Aplidine contains several proline resi-
dues (see Fig. 1F), it could be argued that the inhibitory
effect of Aplidine on the aggregation of PrP 106–126 is
simply produced by non-specific binding to PrP 106–126
through its h-breaking proline residues. In fact, a previous
report shows that it is possible to dissolve PrPsc by co-
incubation with a f 1000 M excess of a peptide mimetic of
the 115–122 sequence of PrP that incorporates several
prolines [18]. However, the inhibitory effect of Aplidine is
not due to proline-mediated interactions with the PrP
sequence. This is indicated by the lack of observableinhibition of PrP 106–126 aggregation by co-incubation
with 10 mM proline (Fig. 1E). Like in the proline-rich
analogs of PrP 115–122 [18], proline residues in Aplidine
are probably involved in breaking the network of hydrogen
bonds required for growth of h-sheets, and not in providing
binding energy. Aplidine at 500 AM concentration is also
able to partially dissolve previously assembled PrP 106–
126 fibrils (Fig. 2), suggesting that the formation of PrP
fibrils is thermodynamically controlled.
To investigate the potential specificity of Aplidine as an
inhibitor of PrP 106–126 aggregation, we carried out
similar experiments with another peptide that aggregates
into h-sheet containing fibrils. As it is shown in Fig. 3A, the
25–35 fragment of the h-amyloid peptide forms well
defined long fibrillar aggregates when incubated in aqueous
solution. Co-incubation with Aplidine results in changes in
the apparent morphology of the aggregates under the
electron microscope. The fibrillar aggregates of h-amyloid
25–35 become thinner and form bundles (Fig. 3B, C and
Fig. 2. Effect of Aplidine on PrP peptide polymers. PrP peptides assembled as indicated in Materials and methods, were incubated in the absence (A), for 1 h
(B), and 2 h (C) at 37 jC. (in the presence of 500 AM Aplidine). Bars indicate 200 nM.
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concentrations, and become more apparent as the concen-
tration of Aplidine increases. However, fibrillar aggregates
can be observed in all the conditions investigated.
One of the critical characteristics of the prion infectivity
model is the existence of a conformational change into h-
sheet structure. The conformational change is thought to
trigger aggregation, leading to formation of infectiousFig. 3. Polymerization of beta amyloid peptide in the presence and absence of A
described in Materials and methods. (B) Polymerization of h-amyloid peptide in th
or (D) 1 mM Aplidine. Bars indicate 500 nm.particles [3]. PrP 106–126 molecules in the fibrillar ag-
gregates have a high content of h-sheet structure [14]. This
is clearly observed in the amide II region of the FTIR
spectrum of PrP 106–126 (Fig. 4A). The amide II band of
PrP 106–126 shows a very intense maximum in the region
near 1620 cm 1 and a weak maximum at f 1680 cm 1,
both indicative of a high content of hydrogen-bonded h-
sheet structure. The FTIR spectrum also shows the pres-plidine. (A) Polymerization of h-amyloid peptide in aqueous solution as
e same conditions, but in presence of 50 AMAplidine, (C) 500 AMAplidine,
Fig. 4. FTIR of PrP 106–126 and h-amyloid peptides in the presence and absence of Aplidine. (A) Amide II region of the FTIR spectrum of peptide PrP 106–
126 in aqueous solution in conditions leading to formation of h-sheet fibrils (triangles), of Aplidine alone (circles), and of peptide PrP 106–126 in the same
conditions, but incubated with a 4-fold molar excess of Aplidine (squares). The last spectrum was obtained as the difference between the FTIR spectrum of the
mixture PrP 106–126/Aplidine and that of Aplidine alone. Spectral regions typical of h-sheet, a-helix and non-hydrogen-bonded conformations are shown for
comparison. (B) As in A, but for the h-amyloid peptide. Amide II region of the FTIR spectrum of h-amyloid in aqueous solution in conditions leading to the
formation h-sheet fibrils (triangles), of Aplidine alone (circles), and of h-amyloid in the same conditions, but co-incubated with a 4-fold molar excess of
Aplidine (squares).
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bonded) conformations. This can arise from some fraying
of the ends of the PrP 106–126 peptide in the h-sheet
aggregate, or from the presence of a small proportion of
soluble monomeric PrP 106–126 peptide. Co-incubation
with a 4-fold mass excess of Aplidine produces a drastic
change in the amide II region of PrP 106–126. The two
maxima mentioned above disappear, while the intensity of
the area corresponding to non-hydrogen-bonded conforma-
tions increases significantly (Fig. 4A). All of this indicates
that upon addition of Aplidine, PrP 106–126 shifts from
h-sheet structure to a set of unstructured conformations. h-
amyloid 25–35 also contains h-sheet structure in its
fibrillar aggregated form. The structure of aggregated h-
amyloid 25–35 is, however, more heterogeneous. FTIR
reveals again a maximum at 1620 cm 1, but with lower
relative intensity than for PrP 106–126. The weak maxi-
mum at 1680 cm 1 is not observed, and the intermediate
bands corresponding to non-hydrogen-bonded conforma-
tions are, in this case, more intense (Fig. 4B). Interestingly,
co-incubation with Aplidine results in only slight changes
in the conformation of h-amyloid 25–35. The decrease in
the intensity at 1620 cm 1 and the increase of the
intensity at f 1665 cm 1 indicate a very small increase
in the structural heterogeneity of h-amyloid 25–35. This is
consistent with the electron microscopy images of the
material, which show fibrillar aggregates in the presence
of Aplidine (see above), and further supports the idea that
the inhibition of the aggregation of PrP 106–126 induced
by Aplidine is much stronger than that observed on h-
amyloid peptide aggregation.4. Discussion
Our results show that Aplidine inhibits the aggregation of
PrP 106–126 and the formation of h-sheet structure that
occurs concomitantly. The inhibitory effect is already de-
tectable at concentrations of Aplidine of only 12% of that of
PrP 106–126, while total inhibition only requires a 1:1
molar ratio. In principle, two mechanisms are conceivable to
explain these results. In the first one, Aplidine inhibits PrP
106–126 aggregation by strongly binding to the monomeric
peptide, sequestering it from the aggregation reaction. The
second mechanism involves binding of Aplidine to the
growing ends of the fibrillar aggregates, thereby blocking
further growth. In the first mechanism, to obtain full
inhibition of aggregation with a 1:1 ratio of Aplidine–PrP,
the binding affinity of Aplidine for PrP would have to be
much greater than that of PrP for itself. Furthermore, it is
difficult to explain the observation of inhibitory effects at
low concentrations of Aplidine with a simple monomer-
sequestering mechanism. The second mechanism can natu-
rally explain both observations, because a small amount of
Aplidine will result in effective reduction of fibril formation
by just transiently capping very short ‘nucleated’ fibrils,
even without a strong affinity to bind PrP 106–126. This
mechanism results in as stronger inhibitory effect and a
potentially more powerful therapeutic agent. Moreover, the
inhibition of PrP 106–126 aggregation by Aplidine is rather
specific. Under the same conditions tested on PrP 106–126,
Aplidine does not significantly inhibit the aggregation of the
h-amyloid 25–35 peptide. Such preferential action on PrP
106–126 aggregates reveals that the inhibitory effect is
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of the PrP 106–126 sequence rather than produced by a
more generic h-breaker ability of Aplidine. Other inhibitors
of prion aggregation that have been described previously
rely on closely mimicking the original prion sequence to
obtain selective binding [17,18]. Aplidine is in fact the first
specific inhibitor that has no sequence homology with the
prion sequence.
The finding of clinical correlations between the obser-
vation of h-sheet protein aggregates deposited in brain
tissue and the onset of prion-related and many other
diseases has resulted in a variety of efforts to identify
inhibitors of these aggregation processes to be used as
therapeutic agents. More recent ideas suggest that the
agents causing these diseases are not the aggregates
themselves, but perhaps small oligomeric precursors of
the fibrillar aggregates [1]. Even if this is the case, the
underlying mechanism of formation of the oligomeric
precursors is presumably still the same, involving a con-
formational change into h-structure followed by intermo-
lecular association. Interestingly, in a recent sophisticated
kinetic study of amyloid formation, it has been found that
aggregation occurs in two phases: first, by the formation of
oligomers, then followed by their accretion into long
fibrillar aggregates [24]. Moreover, the large aggregates
could play a depository role by forming structures that
withstand degradation by proteases from which oligomers
are released slowly. Therefore, finding blockers of h-sheet
aggregation is still a promising strategy to develop thera-
peutic agents for these diseases. In this regard, Aplidine is
particularly promising as a leading compound for drug
development efforts. Previously found inhibitors are based
on the sequence of the prion molecules [18], raising the
possibility of cross-reactions. An excess of f 1000 of the
blocking peptide was required to achieve effective inhibi-
tion [18], compared to the 1:1 ratio that we find for
Aplidine. Moreover, all these molecules were standard L-
amino acid based peptides. Such peptides are typically not
good candidates for drug development because they have a
low tendency to cross the plasmatic membrane and are
very sensitive to the attack of extracellular proteases.
Aplidine is an anti-tumoral agent used in proliferating
cells [19], which by means of its cyclic structure, crosses
the membrane rather effectively and is resistant to protease
degradation. The direct use of this compound for thera-
peutic purposes should be further tested to determine
whether its toxicity level is sufficiently low in neural cells.
Alternatively, Aplidine can be used as a lead compound to
develop derivatives that maintain its preferential inhibitory
effect on PrP aggregation but reduce its potential toxicity.
In summary, Aplidine is a strong inhibitor of the assem-
bly of the prion peptide 106–126 into h-sheet containing
fibrils that works at equimolecular concentrations. More-
over, the strength of the inhibitory effect relies on specific
interactions between Aplidine and the amino acidic se-
quence of PrP 106–126.Acknowledgements
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